Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Senju Study: Ranibizumab Biosimilar Most Cost-Effective Treatment For nAMD In Japan

May 12, 2023

A Senju study has shown that its ranibizumab biosimilar (biosim to Roche/Genentech’s Lucentis®) is more cost-effective in treat-and-extend (TAE) regimens compared to aflibercept based on higher quality-adjusted life-years (QALYs) and lower cost in treating neovascular age-related macular degeneration (nAMD).  The biosim was also cost-saving compared to Lucentis® for both TAE and pro re nata regimens. Senju’s ranibizumab biosimilar was the first ranibizumab biosim in Japan, which demonstrated comparable quality, efficacy, and safety for the treatment of nAMD.

On 25 April 2023, STADA and Xbrane announced they are supplying Ximluci® (ranibizumab) in England under a NHS England Framework Agreement.